B
BioVie
Developing novel drug therapies for life-threatening complications of chronic liver disease
About BioVie
BioVie Inc. is a biopharmaceutical company focused on developing innovative treatments for chronic debilitating diseases, particularly those with limited or no viable alternatives. The company operates in the healthcare and pharmaceutical markets, targeting conditions such as liver cirrhosis, neurodegeneration, and oncology. BioVie's business model revolves around the research, development, and commercialization of novel therapeutic solutions. The company generates revenue through the sale of its proprietary drugs and therapies, which are designed to address unmet medical needs. BioVie serves patients and healthcare providers who are in dire need of advanced treatment options. The leadership team comprises veteran executives with extensive experience in the industry, science, and operations, ensuring a robust and strategic approach to tackling complex medical challenges.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2013
- Headquarters
- Carson City, United States
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US Department of War
Series B and later1 investor entered at this stage
Avenue Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioVie on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioVie on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.